InnoCare Reports Response Rate in Phase II Lymphoma Study
InnoCare said its orelabrutinib combination achieved a response rate in a Phase II study of marginal zone lymphoma.
Related stories
Chipotle Shares Rise 7% Premarket as Traffic Revival Efforts Gain Traction
Chipotle shares rose 7% in premarket trading Thursday. The company expects comparable sales to be up around 3% to 4% as it exits the current quarter.
M impact | EQUITY | Oct 29, 2026, 09:48 AM UTC
Ningbo Port Says Q3 Revenue Rose 3.2% Year Over Year
Ningbo Port said revenue in the third quarter increased 3.2% year over year.
M impact | EQUITY | Oct 29, 2026, 09:47 AM UTC
Ningbo Port Reports Third-Quarter Revenue Up 3.2% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:47 AM UTC
Ningbo Port Q3 Net Profit Falls 17.2% Year Over Year
Ningbo Port said third-quarter net profit fell 17.2% year over year.
M impact | EQUITY | Oct 29, 2026, 09:47 AM UTC
Deye Shares Says Q3 Revenue Rose 97.5% Year Over Year
Deye Shares said third-quarter revenue increased 97.5% year over year.
M impact | EQUITY | Oct 29, 2026, 09:47 AM UTC
Southside Bancshares Reports Q3 Revenue of $74.0M
Q3 revenue was $74.0 million, versus a FactSet estimate of $72.7 million.
M impact | EQUITY | Oct 29, 2026, 09:47 AM UTC